Otsuka Pharmaceutical Development & Commercialization, Inc. Develops Relapse Risk Assessment For Schizophrenia Patients (RASP): A New Self-Report Screening Tool Gettysburg, PA, May 09, 2018 (GLOBE NEWSWIRE) -- Nearly 3.4 million adults, or 1.1% of the U.S. population, are affected by schizophrenia.1,2 As a chronic, relapsing condition, those who have...